The only data I’ve seen for the vaccine is from the following 2 sources:
- The 2014 article published by the MSK group: http://clincancerres.aacrjournals.org/content/20/5/1375.long
- Presentations by Brian Kushner and Shakeel Modak at various patient/parent nb conferences.
I did push Brian Kushner for more information but unsurprisingly he wasn’t very forthcoming!
I think the bottom line is no one really knows if it makes a difference and if so, how much of a difference. There are so many other variables at play in the small number of patients that we are talking about, so you have to be very careful how this limited data is interpreted.
For me, the vaccine:
- makes sense biologically
- seems to have limited significant side effects
- the very limited data presented at conferences suggests there might be an improvement in survival (in patients who have previously relapsed) - but as I say there are so many confounding factors and the trials so far haven’t been set up to answer this question - the only published data I’m aware of is linked above and was a phase 1 trial that primarily investigated the maximum tolerated dose
- and is something we could personally afford (after a lot of fundraising!)
… so for us it made sense to give it a shot!
Sorry I can’t be of more help!